United States - English - NLM (National Library of Medicine)

pure source, llc - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - zinc oxide 95 mg in 1 ml - - helps prevent sunburn - if used as directed with other sun protection measures (see directions), sunscreen decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

ventura corporation ltd - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - octinoxate 0.05 g in 1 ml - - helps prevent sunburn. - if used as directed with other sun protection measures (see directions) decreases the risk of skin cancer and early skin aging caused by the sun.

United States - English - NLM (National Library of Medicine)

science of skincare llc - zinc oxide – 4.20% octinoxate – 3.30% - sunscreen • helps hydrate and prevent sunburn. • if used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skin aging caused by the sun • do not use on damaged or broken skin • stop use and ask a doctor if rash occurs

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection in pre-filled syringe - 15,200 i.u.anti-xa/0.8 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

santen oy - tafluprost - eye drops, solution - 15 microgram(s)/millilitre - tafluprost

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - mannitol - solution for infusion - 15 percent weight/volume - solutions producing osmotic diuresis; mannitol

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - potassium chloride - concentrate for solution for infusion - 15 percent weight/volume - electrolyte solutions; potassium chloride

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 15 microgram/ml (equivalent: desmopressin, qty 13.4 microgram/ml) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for prosthetic valve replacement or aorto-coronary bypass grafting especially when it is complicated by platelet function defects sufficient to prolong bleeding time despite relatively normal platelet cover. desmopressin acetate offers no benefit as routine therapy in patients having an uncomp

United States - English - NLM (National Library of Medicine)

it3 medical llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection, and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration , and adverse reactions ). patients should be switched to alternative analgesics a

United States - English - NLM (National Library of Medicine)

lifetech resources, llc - octinoxate 7.5%, avobenzone 2.0% - sunscreen helps prevent sunburn. higher spf gives more sunburn protection.